Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2026.

August 11, 2026 TAKE/BSE/2026-27 TAKE/NSE/2026-27 The Manager The Manager-Listing Dept. of Corporate Services-Listing Department National Stock Exchange of BSE Limited, India Limited P. J. Towers, Dalal Street, Exchange Plaza, Bandra - Kurla Complex, Mumbai -400001 Bandra (East), Mumbai -400051 Script Code: 532890 Scrip: TAKE Script Id: TAKE Reference: Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"). Subject: Outcome of the Board Meeting held on Tuesday. August 11. 2026. Dear Sir / Madam, In furtherance to our Intimation of Board Meeting dated August 04, 2026, we hereby inform that the meeting of Board of Directors of the Company was held today i.e. Tuesday, August 11, 2026 at the Registered office of the company. The_b oard has considered and approved the following business transactions in the meeting: - - • The Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2026, along with the Limited Review Reports thereon. • Press Release on the aforesaid financial results. The Board Meeting commenced at 05:00 p.m. (IST) and concluded at 06:00 p.m. (1ST). You are requested to take the above cited information on your records. Thanking You, For TAKE Limited (Formerly known as TAK Parmeshvar Dhangare Chairman & Director DIN: 11410125 TAKE LIMITED (formerly known as TAKE Solutions Limited) CIN: L72100TN2000PLC046338 Reg. Office Address: No. B3. No.9, B Block, Alsa Arcade, 3rd Floor, 2nd Avenue, Anna Nagar East, Chennai-600102, Tamil Nadu. Tel: 8108618322 E-mail: investorrelations@takelimited.comWebsite:www.takesolutions.com TAKE Limited delivers strong Ql FY27 Performance with Consolidated Revenue of t30.37 Cr and Net Profit oft 1.06 Cr. Strategic Entry into Biohacking, Science-Backed Nutraceuticals, and Digital Longevity Solutions. YoY Consolidated Revenue Finance Costs Drop 99.6% Consolidated Net Profit Suroes to <30.37 Crore YoY to <0.07 Lakhs After Tax n.06 Cr CHENNAI, August 11, 2026 - TAKE Limited, a global technology-driven healthcare company, today announced its unaudited financial results for the first quarter ended June 30, 2026 (Ql FY 2026-27). Demonstrating significi!nt operational momentum, the Company .delivered Consolidated Revenue from Operations of <3,037.33 Lakhs (<30.37 Crore) and a Consolidated Net Profit of <106.26 Lakhs (<1.06 Crore), reversing a Net Loss of <(91.00) Lakhs in the corresponding prior-year period. KEY FINANCIAL PERFORMANCE HIGHLIGHTS (Ql FY 2026-27) Consolidated Revenue & Total Income: Consolidated Revenue from Operations expanded dramatically to <3,037.33 Lakhs compared to Nil revenue in Ql FY26. Total Income reached <3, 170.11 Lakhs (<31.70 Crore), backed by commercial scaling and execution. Profitability: Consolidated Profit Before Tax (PBT) and Net Profit After Tax (PAT) reached < l 06.26 Lakhs, marking a complete return to profitability compared to a Net Loss of <(91.00) Lakhs in Ql FY26. Finance Costs: Finance costs plummeted by 99.62% YoY to just <0.07 Lakhs (down from < l 7.50 Lakhs in Ql FY26), reflecting debt elimination, interest burden reduction, and a clean capital structure. Earnings Per Share (EPS): Basic and Diluted EPS turned positive at <0.07 per share (Face Value Re. 1/-), up from negative <(0.06) per share in Ql FY26. Standalone Performance: Standal,)ne Revenue from Operations surged to <l,196.90 Lakhs (vs <0.65 Lakhs in Ql FY26), with Net Profit turning around to <96.83 Lakhs (vs a Net Loss of <216.45 Lakhs in Ql FY26). STRATEGIC VISION: DISRUPTING THE LONGEVITY & ANTI-AGEING LANDSCAPE: Building on its restructured, lean balance sheet and deep heritage in life sciences, clinical research, and regulatory execution, TAKE Limited recently announced its strategic entry into India's rapidly accelerating Longevity, Biohacking, and Preventive Healthcare market. TAKE LIMITED (formerly known as TAKE Solutions Limited) CIN:L72100TN2000PLC046338 Reg. Office Address: No. B3. No.9, B Block, Alsa Arcade, 3rd Floor, 2nd Avenue, Anna Nagar East, Chennai-600102, Tamil Nadu. Tel: 8108618322 E-mail: investorrelati9ns@takelimited.comWebsite:www.takesolutions.com Strategic Vectors & Market Opportunity: Expanding Addressable Market (TAM): The global longevity market is projected to grow from USD 27.61 Billion in 2025 to USD 67.03 Billion by 2035 (9.41 % CAGR). In India, the preventive healthcare market reached USD 197 Billion in 2025, with anti-aging supplements expected to expand from US,D 168.6 Million in 2025 to USD 341.4 Million by 2033 (9.5% CAGR) and anti-aging services reaching USD 1.06 Billion by 2035. Dual Business Model: TAKE Limited's strategy integrates science-backed nutraceuticals and biohacking consumer products with technology-enabled predictive digital tools to track and optimize metabolic health, sleep, cognition, and biological aging. High-Margin, Recurring Revenue Potential: The model focuses on high repeat-purchase consumer wellness categories, generating predictable, margin-accretive revenue streams while leveraging existing clinical capabilities for rapid regulatory validation. "Our Qi FY27 results reflect the successful stabilization and revitalization of TAKE Limited's operational framework. With an extremely clean balance sheet, near-zero finm;ice costs, and profitable operations, we are now executing our next growth phase. Our strategic entry into the Longevity and Anti-Ageing sector positions TAKE Limited at the intersection of life sciences, technology, and consumer wellness. By combining our regulatory and clinical domain expertise with cutting-edge biohacking and predictive digital tools, we are building a scalable, high-margin platform that addresses the multi-billion-dollar shift toward proactive health optimization." Parmeshvar Dhangare, Director, TAKE Limited. About TAKE Limited: TJ\KE Limited (Formerly known as TAKE Solutions Limited) is a global technology company delivering domain intensive solutions and services for the life sciences and supply chain industries. With deep expc1tisc in building scalable digital platforms and data-driven solutions, the company focuses on enabling cntc1:prises to improve efficiency, compliance, and decision-making. Through its expanding investments in Al, analytics, and digital health technologies, TAKE Limited is positioning itself to participate in the next wave of innovation, ensuring its solutions address humancentric challenges across healthcare and other knowledge-led industries. TAKE LIMITED (formerly known as TAKE Solutions Limited) CIN:L72100TN2000PLC046338 Reg. Office Address: No. B3. No.9, B Block, Alsa Arcade, 3rd Floor, 2nd Avenue, Anna Nagar East, Chennai-600102, Tamil Nadu. Tel: 8108618322 E-mail: investorrelations@takelimited.comWebsite:www.takesolutions.com A. Raghavendra Rao & Associates., Flat No. SF-2, 2nd Floor, Sampurna chambers, Chartered Accountants No. 13, Vasavi Temple Street, V. V. Puram, Basavanagudi, Bengaluru-560004. Ph:080-26625335,+9194495-34815 INDIA Email: arra.bangalore@yahoo.com INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT OF TAKE LIMITED ON THE QUARTERLY AND YEAR TO DATE UNAUDITED STANDALONE FINANCIAL RESULTS The Management Take Limited Regd. Off. No. 83. No.9, B Block, Alsa Arcade,3rd Floor, 2nd Avenue, Perambur Purasawalkam, Chennai, Tamil Nadu,600 I 02-lndia. We have reviewed the accompanying Unaudited Standalone Financial Results of Take Limited ("the Company"), which comprise the Balance Sheet as at 30thJune 2026 and year to date from 01 st April 2026 to 30th June 2026, the Statement of Profit and Loss and other relevant statements for the period then ended, and a summary of significant accounting policies and other explanatory information ( collectively referred to as the "Quarterly Financial Statements"). Management's Responsibility The preparation of these Quarterly Financial Statements is the responsibility of the Company's Management, including the design, implementation, and maintenance of in [Showing first 8,000 characters — download PDF for full document]